This article discusses the development of smart nanocarriers that respond to endogenous stimuli within tumors, aiming to overcome key barriers in cancer immunotherapy and transform 'cold' tumors into immunologically 'hot' ones.
Cancer Biology & MedicineMay 15 2026 Although cancer immunotherapy has transformed treatment by harnessing the immune system to eliminate tumors, only a small subset of patients benefit.
Many solid tumors remain "cold," characterized by poor immune cell infiltration and resistance to immune checkpoint blockade . In addition, traditional immunotherapies such as cytokines and checkpoint inhibitors often cause severe immune-related adverse events due to off-target toxicity, poor tumor targeting, and the immunosuppressive microenvironment that surrounds tumors. Conventional nanodrug delivery systems face further obstacles including immune clearance, drug leakage, and cellular barriers that limit delivery efficiency.
Based on these challenges, there is an urgent need to develop smarter delivery systems that can navigate the tumor microenvironment and release therapeutic agents with high spatial precision. A research team from the Institute of Biomedical Engineering, College of Medicine, Southwest Jiaotong University in Chengdu, China, has published a comprehensive article on tumor microenvironment -responsive polymeric nanoparticles in Cancer Biology & Medicine.
The article, available online, summarizes recent advances in smart nanocarriers that respond to endogenous stimuli within tumors, highlighting how these systems can overcome key barriers in cancer immunotherapy and transform "cold" tumors into immunologically "hot" ones. The review details multiple types of TME-responsive polymeric nanoparticles, each designed to exploit specific abnormal features of tumors.
For pH-responsive systems, researchers use acid-labile bonds such as hydrazone or imine that trigger drug release in the mildly acidic tumor environment compared to normal tissues . Enzyme-responsive nanoparticles incorporate matrix metalloproteinase -cleavable peptide sequences that enable deep tumor penetration.
For redox-responsive designs, the elevated reactive oxygen species and glutathione levels activate drug release through thioether or disulfide bonds. Hypoxia-responsive systems utilize azo derivatives or nitroimidazoles as sensitive linkers.
The review also highlights multi-responsive platforms that combine two or more triggers, such as ROS/pH dual-responsive nanocarriers ) that deliver the transcription factor 3 inhibitor nicosamide and synergize with oncolytic viruses to induce gasdermin E-mediated pyroptosis. This process remodels the immunosuppressive microenvironment and converts immunologically "cold" tumors into "hot" tumors, dramatically improvingICBefficacy. The authors explained that the real power of these smart materials lies in their ability to respond to the tumor's own signals.
"The tumor microenvironment is no longer just a barrier—it has become an opportunity," they said. "By designing nanoparticles that sense low pH, excess enzymes, or oxidative stress, we can deliver immunotherapy exactly where it is needed and release it only when the conditions are right. This turns the tumor's own features against it.
" They also emphasized that multi-responsive systems are particularly promising because they can adapt to the highly heterogeneous and dynamic nature of tumors, something single-stimulus systems often fail to achieve. This technology holds immediate potential for patients with solid tumors that do not respond to existing immunotherapies, including melanoma, triple-negative breast cancer, glioblastoma, and colorectal cancer.
The ability to precisely control drug release within the TME could reduce severe immune-related adverse events such as cytokine release syndrome and tissue damage, making immunotherapy safer for broader patient populations. Beyond cancer, the design principles of stimuli-responsive nanocarriers may extend to other diseases characterized by abnormal microenvironments, including chronic inflammation and autoimmune disorders. Future clinical translation will require scalable manufacturing, rigorous safety evaluation, and combination strategies with existing ICB and chimeric antigen receptor -T therapies.
Source:Cancer Biology & Medicine Journal reference:Zhang, Y., et al. . Tumor microenvironment-responsive polymeric nanoparticles for enhanced immunotherapy. Cancer Biology & Medicine. DOI: 10.20892/j.issn.2095-3941.2025.0517. https://www.cancerbiomed.org/content/early/2025/12/03/j.issn.2095-3941.2025.0517.
Cancer Immunotherapy Tumor Microenvironment Polymeric Nanoparticles Smart Nanocarriers Endogenous Stimuli Acid-Labile Bonds Matrix Metalloproteinase
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Researchers find new way to deliver drugs directly into cancer cellsNational University of Singapore Researchers at the National University of Singapore (NUS) have developed a high-throughput method to identify gold nanoparticles capable of delivering therapies directly to mitochondria (the energy centres inside cancer cells).
Read more »
Medical Imaging Reveals More Biological Information in Aggressive Head and Neck CancersA study published in the journal Molecular Cancer demonstrates how combining molecular multi-omics with quantitative imaging analysis can move precision oncology forward by establishing a framework linking tumor biology to radiological features. The work suggests that PET/CT scans can identify and monitor high-risk tumors in HPV-negative head and neck cancer, offering new possibilities for diagnosis and treatment planning.
Read more »
New drug carrier improves cancer treatment by anchoring to tumorsMedications are designed to treat diseased tissues while sparing healthy ones, often by attaching the drug to something that helps guide it directly to its target. But drugs also need time to work, which means they need to stay near the diseased tissues long enough.
Read more »
Gene panel predicts chemotherapy response in triple-negative breast cancerResearchers at The University of Texas MD Anderson Cancer Center have characterized cancer cell-specific features in the tumor microenvironment (TME) of early-stage triple-negative breast cancer (TNBC) tissues, identifying specific macrophage subtypes associated with chemotherapy response.
Read more »